View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
Animals Count, which describes itself as a political party for people and animals, will launch its EU election manifesto on 24th May from 12 noon at the Kings Oak, Loughton, where it will be putting into practice one of its proposed policies: subsidised basic and emergency animal health care for animals. Animals Count President and veterinarian, Andrew Knight, will provide free dog consultations and animal health care advice for all companion animals.
Animals Count will contest the European Parliament elections, taking place on the 4th of June. It hopes to end farming with poor welfare consequences for animals, long distance live animal transport, all hunting for sport, and introduce an EU-wide subsidised basic animal health care system.
Animals Count Leader, Jasmijn de Boo MSc., said: "Concern for animals has long been a mainstream priority, yet remains poorly represented by most political parties. In several countries political parties for animals have formed to meet this need. The Dutch Party for the Animals from which we grew now has 20 elected representatives, including 2 MPs and one senator."
"The EU elections are particularly important for people and animals. Around half the EC budget is spent on agriculture. Given today's economic climate there's never been a better time to re-examine the massive expenditure of tax-payer money on farming methods known to be strongly associated with poor animal welfare and serious environmental damage."
Miss de Boo, 33, Alex Bourke, 47, Vice-chair of Animals Count and best-selling author of the 'Vegetarian Guides' book series, and Richard Deboo, 41, City professional and public speaker on animal issues, will contest the June EU elections in the Eastern region of the UK. Animals Count's ultimate goal is a world in which animals are not exploited, and are treated as sentient beings.
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
The RCVS Disciplinary Committee has this week directed that the name of a Grimsby veterinary surgeon should be removed from the RCVS Register, having found him guilty of serious professional misconduct for advising and undertaking surgical procedures without sufficient clinical grounds or considering alternative treatment options; failing to obtain the informed consent of his clients; undertaking procedures outside his area of competence; failing to refer or discuss the option of referral to a specialist; and, failing to provide his patients with adequate pain relief.
Mr Joseph Lennox Holmes, of Waltham Veterinary Clinic, Grimsby, faced nine charges relating to two separate complaints, at a two-week hearing in October which resumed this week.
These complaints concerned four consecutive staphylectomies and a tracheostomy that Mr Holmes performed on Jake, a Cavalier King Charles Spaniel owned by Ms Marsden; the dental treatment he gave to three Persian cats called Dream Topping, Charlie Brown and Henry, together with the advice he gave to their owner, Mrs Auckland.
On 25 October 2007, Mr Holmes performed a staphylectomy on Jake during dental surgery. He gave the Committee various reasons why he thought the procedure was necessary; however, the Committee accepted the opinion of two expert witnesses Professor Dan Brockman, a specialist in soft tissue surgery at the Royal Veterinary College, and Mr Andrew Ash, the senior veterinary surgeon at a 17-vet small animal practice, that there were insufficient clinical grounds for such a surgical procedure to be undertaken. The Committee also found Mr Holmes had not adequately considered other treatments, or obtained fully informed consent from Jake's owner for this procedure.
Mr Holmes performed further staphylectomies and a tracheostomy on Jake, a procedure described by Professor Brockman as "by definition, high risk and best performed by a specialist". He did not consider referral, or inform Mrs Marsden that such referral was an option. Nor did he provide sufficient aftercare or pain relief. Following these surgeries, Jake was euthanased .
In the second complaint, Mr Holmes performed dental extractions on two cats, Dream Topping and Henry, and advised removing teeth from a third, Charlie Brown, in October 2008. The Committee, however, accepted the view of expert witness Mr Ash and Dr David Crossley, RCVS Recognised Specialist in Veterinary Dentistry, that the dental extractions performed, and the advice given, were not justified on the available clinical evidence. The Committee also found that Mr Holmes did not discuss alternative treatment options with Mrs Auckland, or obtain her informed consent. In the case of Dream Topping, consent was sought after the cat had been sedated for an unrelated procedure and Mrs Auckland had felt under pressure to consent.
Mr Holmes had also relied on anaesthesia-inducing drugs to provide analgesia for the dental extractions, without any other form of pain relief. The Committee agreed with the expert witnesses that this was wholly inadequate.
The Committee found many aggravating factors in both cases, including actual injury to animals from unnecessary surgery, and a serious breach of the trust in which Mr Holmes' clients had placed in him to make the welfare of their animals his primary consideration. His repeated misconduct had been sustained over a period of time in the face of a previous adverse finding of the Committee in 2006.
It also found that Mr Holmes failed to appreciate when a case was outwith his experience, and had continued his course of action despite Jake's deterioration; he had not considered referral or accepted that others in the profession might know more than he did; in formulating clinical practice and policies, he made no reference to peer-reviewed literature or continued professional development; and, his use of outmoded drugs and medicines intended for human use was of concern, as was his lack of appreciation of the need for adequate pain relief when performing painful surgical procedures.
Towards the end of the hearing, Mr Holmes said in mitigation that he regretted unreservedly any adverse effects that his treatment had had on the animals concerned, and that he now realised that his long history of working alone had allowed him to become professionally isolated, to become over-confident in the value of his own experience and rather "set in his ways".
Having given serious consideration to postponing judgment, subject to undertakings from Mr Holmes, Disciplinary Committee Chairman Mrs Caroline Freedman said: "We are mindful that the sanction which we apply must be proportionate to the nature and extent of the misconduct found proved and must balance the public interests against the interests of the Respondent.
"We are, however, also mindful of Mr Holmes' conduct during the previous 11½ days of the hearing, during which time his every action was vigorously defended and no insight whatsoever was shown."
The Committee also considered suspending Mr Holmes from the Register. "In view of the serious and long-term nature of the conduct found proved in the charges, we do not feel that it is appropriate that Mr Holmes should be permitted to return to the Register without further assessment of his efforts to update his knowledge," said Mrs Freedman, before concluding: "The only appropriate sanction in each case is that the Registrar be directed to remove Mr Holmes' name from the Register."
The new practice was created by refurbishing the premises of what was a purpose-built human hospital, turning it into a referral clinic with two operating theatres, separate accommodation and waiting rooms for cats and dogs, offices and a seminar room.
Funding for the refurbishment came from NatWest, with further funds for things like digital radiography and a CT scanner coming from Lombard Asset Finance.
Martin said: "We decided to open East of England Veterinary Specialists to offer a more personal, yet professional service for pet owners in the local community. Thanks to the funding from NatWest and Lombard, we have been able to create a well-equipped surgery where we can offer the highest level of veterinary orthopaedic expertise.
"We have enjoyed welcoming our first customers over the past month and look forward to continuing to establish ourselves as an expert orthopaedic veterinary clinic, where 100% of referred cases will be managed by a Recognised Specialist."
For more information, visit: https://eoevets.com or telephone 01223 795023
Photo: L-R Karl Simper, relationship manager at NatWest, Martin Owen, co- founder of East of England Veterinary Specialists, Mat Parkhouse relationship manager at NatWest and Mark Bush, co- founder of East of England Veterinary Specialists.
Licensed for the treatment of severe equine asthma, each Equipred tablet contains 50mg of prednisolone, a larger concentration tablet designed to make dosing easier.
Equipred tablets are available in boxes of 100 tablets and each tablet can be divided into halves and quarters for accurate dosing and precise tapering of the administered dose.
Rosie Naylor, Equine Technical Product Manager at Virbac said: "We are pleased to add Equipred to Virbac’s equine range. The novel 50mg tablet presentation will enable accurate dosing of horses that require orally administered steroid treatment".
For more information, contact your Virbac Territory Manager.
Cosacthen contains 0.25 mg/ml of tetracosactide which had only previously been available as human-registered or compounded veterinary ‘special’ preparations meaning availability and cost could be unpredictable.
Tetracosactide is used in the ACTH stimulation test to assess the adrenocortical function of patients with endocrine diseases, such as Cushing’s and Addison’s.
Dechra Brand Manager Claire Morgan said: “As experts in endocrinology, we recognise that the testing involved in adrenal conditions can be a costly process for pet owners, which can mean that some cases don’t progress to treatment or have their treatment optimised.
"The launch of Cosacthen gives veterinary surgeons the reassurance associated with a veterinary licensed medicine. As these cases can appear on an irregular basis, Cosacthen is ideal to keep in the practice ready for when a case is presented making it a cost-effective solution that can help offset the cost for owners of long-term treatment of adrenal conditions."
Cosacthen is available in 1 ml single-use vials.
For more information visit www.dechra.co.uk/cosacthen.
The company’s NEMO Cardiac Health Screening test detects heart disease using AI to analyse microRNAs - biomarkers that manage the immune system and its responses and act as regulators for disease progression or resolution.
MI:RNA says the new test, which can be taken from blood or urine samples, will help vets diagnose and monitor disease progression more effectively and give cats and dogs with heart disease 18 months more life.
Eve Hanks, CEO and founder of MI:RNA (pictured) said: “The use of precision medicine in veterinary diagnostics will help pet owners and breeders alike to ascertain where to direct their efforts and finances accordingly.
"There is massive potential to use this technology to help breeds who have real problems with heart and other diseases, and will consequently help owners and breeders to identify affected animals more quickly.
Professor Joanna Dukes-McEwan, Head of the Cardiology Service at the University of Liverpool said: "From our cardiac investigations, we knew exactly the underlying heart disease and the severity of this, so our data was used as a training set for the MI:RNA panel analysis.
"We have previously collected samples from dogs with myxomatous mitral valve disease and are currently collecting samples from cats with hypertrophic cardiomyopathy.
“I think the MI:RNA panels are most useful for vets in primary care practice to identify and confirm the severity of underlying cardiac disease in their patients.
"A simple blood test which could confirm that the cause of a heart murmur is MVD, and also indicate its severity, and whether the patient would benefit from treatment would be really helpful for primary care vets in practice.
"They might indicate which patients may benefit from referral, or indicate when a specific treatment is indicated.
"Future research with miRNA panels may also indicate novel pathways in progression of disease which might increase our understanding of the disease, or novel therapeutic options.”
Corona Detect is a first-line screening tool for detecting exposure to feline coronavirus (FCoV). It can be coupled with the Idexx FIP Virus RealPCR to follow up coronavirus-positive cats exhibiting clinical signs suspected to be FIP. The Idexx FIP Virus RealPCR evaluates for mutations of feline coronavirus to the pathogenic FIPV biotype.
Idexx says that this new two-tier diagnostic approach will help veterinary surgeons rule out or positively diagnose FIP, a condition which has hitherto been extremely difficult and frustrating to diagnose.
Simon Wootton, Idexx’s Companion Animal Group’s Northern European Marketing Manager said: "FIP is a terrible disease, so being able to screen and either confirm or rule out exposure to FCoV is an important additional step in the diagnosis options available to vets. With the ability to screen in minutes, practitioners will be able to decide whether to perform confirmatory and potentially invasive tests for the specific FIPV mutations. This obviously brings benefits to aid pet owners."
Further information is available on the company’s website – www.idexx.eu
Merial has announced that its canine NSAID, Previcox, is now now uniquely licensed for the relief of pain and inflammation associated with dental surgery in dogs.
According to the company, an estimated 70% of dogs over 2 years of age may have some degree of periodontal disease1, and painful extraction of teeth is often necessary for the successful management of this condition.
Merial says that Previcox has been demonstrated to control the pain associated with dental surgery, in a double-blinded, controlled trial2 in which dogs underwent maxillary canine tooth extraction. The results showed that Previcox treatment significantly reduced pain scores post dental surgery, making it the only NSAID with a specific claim for relief of post-operative dental pain. Results of physical examination and blood testing also confirmed the peri-operative safety profile of Previcox, with no treatment-related adverse effects noted during the trial.
To find out more, contact your Merial Territory Manager on 0870 6000 123. For more information about Previcox visit www.previcoxfordogs.co.uk
References
1 Wiggs RB and Lobprise HB. Periodontology. In: Veterinary Dentistry, Principles and Practice. Philadelphia: Lippincott-Raven; 1997. p1872 Merial Internal data PR&D0116401.
Norbrook is expanding its NSAID range with the launch of Loxicom Injection for cattle, pigs and horses.
Norbrook says the new product, which will be available to veterinary surgeons from mid-October, offers treatment for a range of symptoms including pneumonia, acute mastitis and calf scour in cattle, swine locomotor diseases such as lameness and MMA syndrome, acute and chronic musculo-skeletal disorders and equine colic.
Rebecca Pullon, Norbrook Product Manager said: "Loxicom is our tried and trusted NSAID range which has been available in suspension or injection for cats and dogs and which has proven exceptionally popular with veterinary practices. According to the GFK data, Norbrook is the most successful generic manufacturer of Meloxicam, by some distance.
"I am delighted that we can now extend this range to include a Loxicom Injection for Cattle, Pigs and Horses, which I am confident will prove equally as popular."
"As a bio-equivalent product, Loxicom Injection for cattle, pigs and horses is as effective as the pioneer product. There is a misperception that a bioequivalent product is somehow inferior to the pioneer product, which is untrue. In order to attain a license, a company must prove that a bio-equivalent product is at least as effective as the pioneer. With Loxicom Injection for cattle, pigs and horses, it comes with the added reassurance that it has been produced by Norbrook, a world leader in animal health and veterinary pharmaceuticals manufacture."
MSD's push is being driven by the rising number of cases of Leishmaniasis cases in the UK, including the first report earlier this year of dog-to-dog transmission of the disease.
Caroline Darouj, Product Manager at MSD Animal Health said: "Whilst accurate statistics on the number of cases seen in UK practices are not available, the VMD has reported an annual increase in the number of leishmaniasis treatments imported since records started in 2006.
"Based on applications for Special Import Certificates for Milteforan and Glucantime, there were 27 times as many cases treated in 2018 (439) compared to 2006 (16)*.
"Leishmaniasis is proving to be a significant threat to travelling dogs, a situation that has been widely reported in the vet press, so LetiFend will offer veterinary practices and dog owners throughout the UK reassurance. A single dose primary course given four weeks before travel makes it ideal for non-regular travelers."
Letifend is indicated to reduce the risk of developing active infection and/or clinical disease after exposure to L. infantum from 28 days post vaccination1,2. It offers protection for 365 days after a single annual dose. The company says it has excellent tolerability shown in a wide range of breeds and ages, and in field trials in areas at high risk of infection had an efficacy rate of 72%4.
LetiFend is a non-adjuvanted vaccine which MSD says ensures a targeted immune response with a high level of safety.
MSD says a dog vaccinated with LetiFend is at 9.8 times less risk of presenting clinical signs, at 3.5 times less risk of presenting parasites, and thus at 5 times less risk of developing clinical leishmaniasis1. It can be applied from six months of age via subcutaneous administration.
For further information contact your MSD Animal Health account manager.
*Information from VMD following a Freedom of Information Act request.
177 delegates took part in the survey, which found that even the most commonly used digital tool, namely automated reminders, are not being used by more than a third of all practices.
Less than 60% are using digital records.
Less than half are using online booking, which Provet says can significantly improve the customer experience.
Less than 20% have implemented integrated payments or telemedicine or pet owner apps.
The survey also found that 42% are still using old server technology, rather than cloud-based solutions (28%).
The company has produced a guide to what you should look for in a practice management system, including pros and cons of cloud vs. server-based solutions and digital tools that can improve service level whilst saving time, which you can download here.
Fiproclear Combo, which contains fipronil and S-methoprene, is licensed for use on cats and dogs and can also be used to treat and prevent fleas and ticks on ferrets.
Norbrook says the new product provides effective protection from new flea infestations for up to eight weeks on dogs and four weeks on cats, while protecting against certain ticks for up to four weeks on dogs, and two weeks on cats.
Monica Whistler, Norbrook Marketing Product Manager, said: "With its triple-action approach, Fiproclear Combo kills adult fleas, ticks and biting lice. The addition of S-methoprene to the already-trusted ingredient fipronil, breaks the flea life cycle in the home by ensuring that any eggs laid by the fleas, which have come into contact with the product are infertile, and by preventing development of flea larvae within a pet’s surroundings.
"Adult fleas on pets are killed within 24 hours whilst newly arrived ticks are killed within 48 hours of attachment – before the main risk period of disease transfer. Ticks rank second only to mosquitoes as insects that spread infectious diseases to both pets and people1; the most common of which is Lyme disease."
Norbrook highlights research which showed almost a third of cats suffered from ectoparasites2, while around one in every three dogs are affected by ticks3, and that many traditional treatments do not help break the flea life cycle in the home.
Monica added: "Typically, by the time an owner notices a flea problem, an infestation has already been present for up to two months. At that point the visible adult fleas on the pet are only part of the problem, with 95% of the parasites already living in the home itself as eggs, larvae and pupae."
Skin diseases and palpable masses are a common presentation in guinea pigs brought for veterinary care2.
However, few studies have thus far looked at the prevalence of spontaneously arising diseases in pet guinea pigs.
"Lumpy bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology" retrospectively analysed 619 biopsy samples submitted for histopathology from pet guinea pigs that had presented with externally palpable masses.
The purpose was to determine the most common tissue origins of these masses and the most frequent pathological diagnoses, together with signalment data for the most commonly diagnosed lesions.
Of the 619 samples submitted from 493 animals, 54 (8.7%) had arisen from the mammary glands3 and 15 (2.4%) from the thyroid glands, with the remaining 550 (88.9%) involving the skin and subcutis, muscle (n = 1), salivary glands (n = 4), lips (n = 2), ears (n = 4) and peripheral lymph nodes (n = 23).
Forty-seven (7.6%) of the masses were diagnosed as inflammatory in nature, including dermatitis, panniculitis, lymphadenitis, cheilitis, myositis, sialoadenitis, abscess and chronic inflammation with osseous metaplasia.
Non-neoplastic, non-inflammatory lesions accounted for a further 31 (5.0%), namely cysts, hamartomas, hyperplastic lesions, polyps, ectopic bone formation and salivary gland steatosis.
The remainder of the samples were neoplastic in nature (541; 87.4%), with 99 masses classified as epithelial in origin, 347 as mesenchymal, 23 as round cell, five as melanocytic and eight as unclassified malignant neoplasms.
Of these, mesenchymal neoplasms were further subdivided into benign (288) and malignant (59).
Lipomas were the most common neoplasm diagnosed, accounting for 286 of all samples submitted.
Of all 619 samples included in the study, the eight most commonly diagnosed lesions were lipoma (46.2%), trichofolliculoma (12.3%), sarcoma (of various subtypes: 9.5%), inflammation (all sites 7.6%), lymphoma / leukaemia (3.4%), mammary carcinoma (4%), mammary adenoma (3.2%) and thyroid carcinoma (1.5%).
Overall these eight diagnoses accounted for 87.7% of all submissions from the externally palpable masses from the pet guinea pigs submitted for histopathology.
Melanie said: “Guinea pigs are an increasingly popular household pet.
"Skin diseases, including palpable masses, are a common reason for veterinary presentation. But few studies have been published to date that provide information for clinicians about these conditions.
“This study illustrates the importance of neoplasms of the skin and subcutis in pet guinea pigs, with over 87% of the cases analysed having one of eight diagnoses.
"While most of these neoplasms are benign, a substantial minority are malignant and identifying those lesions is especially important in treatment planning.
"Clinicians dealing with pet guinea pigs should also be aware that some externally palpable masses may arise from the thyroid or mammary glands rather than the skin or subcutis, and that male guinea pigs may also develop mammary lesions.”
The paper has been selected as ‘Editor’s Choice’ by the Journal of Comparative Pathology and will be free to access until September on Lumpy, bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology - ScienceDirect.
The one hour meeting will take place at 8:00pm on Wednesday 5th May. It will be recorded and available after the event. Simon will begin with a brief background to IR35 and how the system has worked historically. He will then explain what has changed and what the options are for locums (and the impact on their income). The meeting will consider things like the criteria that locums need to fulfill to qualify as sole traders, how to use CEST and alternatives to IR35. There will then be an opportunity to ask questions. All registrants are being invited to submit questions in advance, and the plan is that on the night, groups of four participants will be invited to put their questions to Simon together, in a sort of mini discussion. This'll be repeated as many times as possible within the hour. The meeting is the first in a series planned for VetSurgeon and VetNurse members to meet up, share ideas and make better connections with each other. To register, visit: https://us02web.zoom.us/meeting/register/tZ0rf-GurDIsGdP7UXuJn8TJChZiyXMbdKP_
For more information about Moore Scarrott, see: https://www.moore-scarrott.co.uk
A survey carried out in 2008 by the British Veterinary Association and its student branch, the Association of Veterinary Students (AVS) has found that that one in three students find themselves in difficult or severe financial situations, more than half have suffered from stress, over a fifth from depression, over a quarter from anxiety and one in every 14 from an eating disorder.
The survey also found that some veterinary schools have almost doubled their intake of overseas veterinary students since the survey was last conducted in 2005.
Other key findings from the survey included:
The AVS suggests that there are opportunities for veterinary schools and the veterinary profession to improve the bleak financial picture for students. BVA already provides support meetings for young professionals and has put together a position statement which will kick-start a lobbying process for:
BVA President Nicky Paull said: "The BVA/AVS survey, a part of the BVA's continuing work on behalf of veterinary students, once again continues to highlight the growing problem of debt. This is a particular problem for veterinary undergraduates whose five year course by definition will attract more debt than the average three year undergraduate course.
"The impact of this increasing debt is twofold. Firstly, new graduates are more likely to choose their first jobs on the basis of salary and reducing debt rather than individual professional development. Secondly, we are concerned that as school leavers make career decisions on financial grounds, only those from relatively affluent backgrounds will choose the veterinary profession. This is contrary to the aims of Government to promote the DfES/Gateway to the Professions initiative. It would be sad to see such a vitally important undergraduate course become one which can only be undertaken by talented young people from families who feel they can afford to help with the long term costs.
"The veterinary undergraduate course is not only training future veterinarians on animal health and welfare but also in the essential role vets play in food safety and the health of the nation."
The full survey results can be downloaded here.
The RCVS has released the photograph of a man apprehended by Wiltshire police whilst working as a bogus veterinary surgeon at a practice in Swindon.
Peter Keniry, who had been practising under the name of a properly qualified and legitimately registered veterinary surgeon Shaun Kehoe, was arrested on 23 August and appeared in Swindon Magistrates' Court on charges of fraud and practising veterinary surgery unlawfully. He was released on bail.
Mr Keniry is no stranger to the College or the police, and has already been dealt with in 1998, 2001 and 2005 for similar offences. On each occasion, Mr Keniry has impersonated a member of the College whose name is legitimately on the Register, which makes it difficult even for practices that do check the credentials of prospective employees.
Gordon Hockey, Head of Professional Conduct and Assistant Registrar at the RCVS said: "We were alerted to the potential fraud on 23 August and immediately liaised with the police to facilitate Mr Keniry's arrest that same day. The next day, RCVS Council member Dr Bob Moore and I visited Swindon police station to assist the police.
"It appears that Mr Keniry has continued his pattern of re-offending, and we hope that by publicising his photograph any other practice that has employed him recently will recognise him and contact the RCVS Professional Conduct Department, and potential employers and locum agencies will keep his photograph to reduce the chances of this happening again."
The RCVS Professional Conduct Department can be contacted on: profcon@rcvs.org.uk or 020 7202 0789.
Virbac has been granted a Limited Marketing Authorisation in the UK for its Gudair vaccine, indicated for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (MAP).
MAP is the causal organism for Johne's Disease, a chronic infection of the intestinal system for which there is no cure.
According to Virbac, Johne's Disease enters most flocks following the introduction of infected stock, often breeding rams, bought at markets without checks on disease provenance. It is then spread by the faeces of often apparently healthy animals but which can contain huge numbers of MAP. The main clinical sign is a thin ewe resulting in poor productivity followed by inevitable death. It can be passed between sheep and cattle.
Ovine Johne's Disease (OJD) in sheep is widespread in Australia where annual death rates of up to 17% have been seen in infected flocks. Virbac says that trials conducted there have demonstrated that vaccination with Gudair can reduce the number of deaths due to OJD by 90% and reduce the numbers of OJD-causing organisms excreted in sheep faeces by 90%.
Ken Sibley MRCVS, Technical Advisor at Virbac says that the number of infected flocks in the UK is unknown and the disease often remains undiagnosed: "Johne's Disease can be a significant cause of loss in infected sheep flocks because of reduced productivity and high culling rates. Vaccination provides the only possible assurance when sourcing sheep from potentially infected flocks and will help to reduce losses from the disease should a farmer inadvertently introduce sheep into an infected flock.
"Lambs identified as replacements should generally be vaccinated between 4 and 16 weeks of age, subcutaneously behind the ear. Sheep over 16 weeks of age can also be vaccinated as this will reduce shedding of organisms in infected animals while bought-in replacements can be vaccinated on arrival at the farm. Sheep require only one vaccination for their lifetime.
"Following its success in Australia, we are delighted to be able to offer Gudair to veterinary surgeons in the UK."
For further information, contact your Virbac territory manager or call: 01359 243243
The service will be available to veterinary practices that use more than £250/€300 of Royal Canin urinary diets per year.
The company has enlisted the support of an independent laboratory to carry out an infrared spectroscopy analysis of the stones, in order to make a quantitative and qualitative assessment of their composition. Royal Canin says that by appreciating the mineral-type in all layers, the best dietary recommendation can be made.
Lee Danks, Royal Canin’s Veterinary Scientific Support Manager, said: "Managing cat and dog urolithiasis can be challenging. This valuable service will improve practices’ diagnostic capacity, enabling a better understanding of a patient’s condition and a much more individualised approach to treatment and long-term prevention."
Royal Canin says there are many complex and interacting contributors to urinary stone formation1. Dietary modifications can influence urine pH, the concentration of minerals within the urine and most critically, urine turn-over through the bladder2. The many interactions between promotors and inhibitors of urolithiasis highlight just how critical a tailored nutritional approach can be to the long-term health of urinary patients.
The charity says it joins mounting evidence that brachycephalic cats, including most modern Persians or Exotic Shorthairs, are suffering from a number of health problems, including breathing problems, eye inflammation, skin infections and difficulty eating.
In the study, published open access in the journal PLOS ONE, cat owners were asked to complete a detailed health questionnaire and submit photographs of their cats so that researchers could measure the muzzle ratio and nose position ratio. 1000 valid questionnaires and 373 valid photographs were received.
The research confirmed that flatter-faced cats (of breeds such as the Persian or Exotic Shorthair), were more likely to have breathing problems and that the breathing difficulties were also associated with increased tear staining and a more sedentary lifestyle.
A previous paper, published in the Journal of Feline Medicine and Surgery (JFMS)2 showed how the skulls of brachycephalic cats are actually deformed, especially the nose and jaw.
The charity says that unfortunately, breeds of cat and dog with flat faces are becoming more and more popular, and extremes (of an already abnormal anatomy) can become instant internet celebrities. These breeds and individuals often have large or prominent eyes which are considered by some to be 'cute' because they are baby-like, and the flattened face often has an up-turned or down-turned mouth, which gives it a human or cartoon characteristic of smiling or scowling, such as Grumpy Cat.
Claire Bessant, Chief Executive of International Cat Care said: "It is very depressing to see the life which has been deliberately dealt to some breeds of cats because of a human desire to develop a certain look. I urge cat lovers to speak out and help others to understand that this is not something we should be doing to cats, and not something we should be tolerating.
"One of the best and most beautifully naturally designed animals – the cat – would not normally have any of these problems; we have created them through selective breeding.
"We should not be encouraging people to breed these cats by calling them 'cute', by being amused at their facial characteristics, or by the fact that they snore – rather we need to understand that this is human intervention that is wholly detrimental to the welfare of the cats and is simply cruel.
"International Cat Care takes an ethical view of all cat breeds and our website (http://icatcare.org/advice/cat-breeds) outlines the problems that exist for some breeds, including very flat-faced cats in the Persians and Exotic breeds. Our stance is that we should never deliberately breed cats for any feature or characteristic that impairs their welfare."
BVA President Sean Wensley said: "The UK's decision to leave the European Union will have a significant impact on matters of interest to the veterinary profession, particularly in relation to regulation, education, and workforce planning, but also in terms of animal welfare, research, surveillance, and animal movements.
"BVA will work hard to ensure the voice of the veterinary profession is heard during the negotiation and discussions that will now begin, in order to secure the best possible outcomes for our profession and for animal health and welfare in the UK. The Vet Futures report provides an excellent summary of issues we need to consider in those discussions, and the Vet Futures Action Plan, due to be launched at the Vet Futures Summit on 4 July, outlines key initiatives that we need to take forward, albeit with revised timelines while the full impact of Brexit is determined.
"BVA will retain an outward looking and inclusive perspective through our relationships with international partners, including the Federation of Veterinarians for Europe (FVE), Commonwealth Veterinary Association (CVA) and World Veterinary Association (WVA) to ensure the UK veterinary profession continues to influence and engage on cross border issues such as disease surveillance, veterinary medicines and antimicrobial resistance."
EthyCalm is sprayed directly on the skin, or, for more fractious patients, can be applied with a swab.
Invicta says that unlike other products the effect is instant and EthyCalm leaves no residue on the skin surface.
The improved product, EthyCalm Plus, contains 50% more product (good for over 100 applications) and incorporates a new 'on-off' switch for easier application. It is also now packed in a 'no-roll' case to protect from damage.
Rob Watkins, Managing Director of Invicta, said: "EthyCalm has been an incredibly popular product with nurses and vets. As a small company we always listen to our customers and have taken the opportunity to incorporate suggestions for improvement. The result is EthyCalm Plus which offers significant enhancement over the original product".
EthyCalm Plus is available from veterinary wholesalers and for a limited time the price has been held at £25 each.
Nutricat, a supermarket cat food launched this year, has released the results of a survey which, it says, shows that modern day lifestyles are resulting in British cat owners anthropomorphising their cats.
The survey found that 54% of cat owners believe their cat shares similar emotions to them, 40% sign greetings cards from their cat, and 1/3 say their cat is a better listener than their partner.
Anthropomorphism is nothing new, and since the press release came from a supermarket brand, it would ordinarily have been destined for the 'Deleted Items' folder.
However, one thing caught my eye. In the press release, Nutricat was described as: a new brand of veterinarian approved advanced feline nutrition'.
But it's not just how Nutricat is described in the press release. The title of the Nutricat website is: 'Veterinarian approved cat food', and the words 'veterinarian approved' appear no less than 3 times on the home page. It doesn't stop there. Tesco seems to have got the message too.
So how many veterinary surgeons are required to endorse something in order to claim, reasonably, that it is 'veterinarian approved'. A couple of RCVS Specialists in Feline Medicine? 10 general practitioners? 20? 50? 100?
VetSurgeon.org rang the PR agency for Nutricat and asked the question.
The answer is one.
What do you think? Take part in our poll, here: http://www.vetsurgeon.org/forums/t/9928.aspx
The company says VeggieDent Zen provides the same dental benefits as VeggieDent FR3SH Dental Chews, but also includes L-theanine.
L-theanine is an amino acid which Virbac says is known to positively influence GABA levels in the brain to help reduce anxiety and increase mental focus. According to the company, one VeggieDent Zen chew daily can help to calm and reduce anxiety in dogs whilst also providing regular oral care.
VeggieDent Zen is free from GMO corn, wheat, gluten and meat, and contains no colourants or artificial ingredients. The new chews also hold the Veterinary Oral Health Council (VOHC) seal for tartar control.
Claire Lewis, Product Manager at Virbac said: "Dental chews are a great way for pet owners to provide passive dental care at home. With VeggieDent Zen we are pleased to be able to offer pet owners a convenient, multi-functional approach to supporting their pet’s health and well-being."
VeggieDent Zen comes in 4 chew sizes (Extra-Small, Small, Medium & Large) and is available from the veterinary wholesalers now.
For information on VeggieDent Zen, contact your Virbac Territory Manager.